Quantcast

Pharma news

AstraZeneca’s Imfinzi improves overall survival in trial for cell lung cancer

AstraZeneca and MedImmune, its global biologics research and development arm, on Friday reported positive overall survival (OS) results for the

Posted in Approval, news | Tagged , , , | Leave a comment

Lilly to seek replacement for oncology president

Eli Lilly said Thursday its senior vice president and president of Lilly Oncology, and the member of the company’s executive

Posted in Approval, news | Tagged , | Leave a comment

Novartis’s Zessly approved in Europe

Novartis’s Sandoz has secured European Commission’s approval for biosimilar Zessly, the company said Thursday.

Posted in Approval, news | Tagged , , , | Leave a comment

Real-world evidence shows weight loss in people receiving Saxenda

People treated with Saxenda for weight management lost an average of 8.1 kg after six months in a real-world clinical

Posted in Approval, news | Tagged , | Leave a comment

Lilly’s psoriasis treatment first FDA approved to include data in psoriasis involving the genital area

Eli Lilly said Tuesday that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz injection 80 mg/mL to

Posted in Approval, news | Tagged , , , | Leave a comment

Circassia Pharmaceuticals presents positive data from tested long-acting muscarinic antagonists

Circassia Pharmaceuticals showed positive clinical data from two studies of Tudorza and Duaklir, nearing the a deal with AstraZeneca in the United

Posted in Approval, news | Tagged , | Leave a comment

4D pharma to investigate MRx0518 in multiple cancer settings

The Medicines and Healthcare products Regulatory Agency (MHRA) has cleared 4D pharma’s Clinical Trial Application for MRx0518, a live biotherapeutic

Posted in Approval, news | Tagged , , | Leave a comment

AstraZeneca gets Lokelma approval

The US Food and Drug Administration (FDA) has approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of adults

Posted in Approval, news | Tagged , | Leave a comment

FDA approves Aimovig for migraine

The US Food and Drug Administration (FDA) has approved Novartis’s and Amgen’s Aimovig (erenumab) for the preventive treatment of migraine in

Posted in Approval, news | Tagged , , | Leave a comment

Sanofi, Regeneron explore Dupixent’s role in targeting Type 2 inflammation as an underlying cause of atopic dermatitis

Sanofi’s pivotal Phase 3 test of Dupixent (dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents met its primary and key secondary

Posted in Approval, news | Tagged , , , | Leave a comment